Oliver Luxxe Assets LLC Boosts Holdings in CVS Health Corporation $CVS

Oliver Luxxe Assets LLC grew its stake in shares of CVS Health Corporation (NYSE:CVS) by 26.3% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 134,539 shares of the pharmacy operator’s stock after buying an additional 28,052 shares during the period. CVS Health makes up 2.0% of Oliver Luxxe Assets LLC’s investment portfolio, making the stock its 3rd biggest holding. Oliver Luxxe Assets LLC’s holdings in CVS Health were worth $13,918,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its stake in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. bought a new stake in shares of CVS Health in the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health during the 4th quarter worth approximately $28,000. Global Trust Asset Management LLC increased its position in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new position in shares of CVS Health in the fourth quarter valued at $28,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported second-quarter adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. Management raised its 2026 adjusted EPS outlook to $7.90–$8.10, supported by improving performance at Aetna and strength in the retail business. CVS Health earnings and GLP-1 partnership article
• Positive Sentiment: The company expanded its collaboration with Eli Lilly on GLP-1 weight-management treatments. The initiative could help CVS combine its pharmacy, insurance and care-delivery assets to capture a larger role in the growing obesity-treatment market. CVS GLP-1 strategy article
• Positive Sentiment: Analysts have modestly increased their fair-value estimate for CVS from $111.92 to $114.88, reflecting more constructive views following the earnings results, although execution and policy risks remain. CVS fair value estimate article
• Neutral Sentiment: Healthcare was among the sectors receiving defensive ETF inflows, which may provide some broader investor support for CVS, but the flows were concentrated largely in broad-market funds, Treasuries and gold rather than being a company-specific catalyst. Weekly ETF flows article
• Negative Sentiment: Executives warned that Caremark pharmacy-benefit-management membership could decline in 2026 and that changes involving the 340B drug-pricing program may remain a headwind into 2027. These comments overshadowed the earnings beat and guidance increase by raising concerns about future revenue and profit growth. CVS earnings call risks article

CVS Health Stock Performance

CVS Health stock opened at $95.61 on Friday. CVS Health Corporation has a 52-week low of $63.30 and a 52-week high of $110.68. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a fifty day moving average price of $102.26 and a two-hundred day moving average price of $87.74. The firm has a market capitalization of $122.28 billion, a P/E ratio of 25.29, a P/E/G ratio of 0.87 and a beta of 0.61.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Wall Street Analyst Weigh In

Several brokerages recently commented on CVS. Morgan Stanley raised their target price on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. UBS Group lifted their target price on shares of CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a research report on Thursday. Truist Financial upped their target price on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Finally, HSBC reissued a “hold” rating and issued a $103.00 price target on shares of CVS Health in a research report on Monday, July 6th. Twenty-two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $106.46.

Insider Activity

In other news, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 3,372,000 shares of company stock valued at $317,473,598 in the last three months. Insiders own 0.85% of the company’s stock.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.